Intranasal bovine β-defensin-5 enhances antituberculosis immunity in a mouse model by a novel protein-based respiratory mucosal vaccine

References

• World Health Organization (WHO). Global Tuberculosis Report 2021.
   Google Scholar
• Garnier T, Eiglmeier K, Camus JC, et al. The complete genome sequence of mycobacterium bovis. Proc Natl Acad Sci USA. 2003;100(13):7877–7882. DOI:10.1073/pnas.1130426100
   PubMed Web of Science ®Google Scholar
• Olea-Popelka F, Muwonge A, Perera A, et al. Zoonotic tuberculosis in human beings caused by mycobacterium bovis —a call for action. Lancet Infect Dis. 2017;17(1):e21–5. DOI:10.1016/S1473-3099(16)30139-6
   PubMed Web of Science ®Google Scholar
• Scott C, Cavanaugh JS, Pratt R, et al. Human tuberculosis caused by Mycobacterium bovis in the United States, 2006–2013. Clin Infect Dis. 2016;63(5):594–601. DOI:10.1093/cid/ciw371
   PubMed Web of Science ®Google Scholar
• Müller B, Dürr S, Alonso S, et al. Zoonotic Mycobacterium bovis –induced tuberculosis in humans. Emerg Infect Dis. 2013;19(6):899–908. DOI:10.3201/eid1906.120543
   PubMed Web of Science ®Google Scholar
• Torres-Gonzalez P, Cervera-Hernandez ME, Martinez-Gamboa A, et al. Human tuberculosis caused by mycobacterium bovis: a retrospective comparison with mycobacterium tuberculosis in a Mexican tertiary care centre, 2000–2015. BMC Infect Dis. 2016;16(1):657. DOI:10.1186/s12879-016-2001-5
   PubMedGoogle Scholar
• Ahmed A, Rakshit S, Adiga V, et al. A century of BCG: Impact on tuberculosis control and beyond. Immunol Rev. 2021;301(1):98–121. DOI:10.1111/imr.12968
   PubMed Web of Science ®Google Scholar
• Marais BJ, Buddle BM, de Klerk-Lorist LM, et al. BCG vaccination for bovine tuberculosis; conclusions from the Jerusalem one health workshop. Transbound Emerg Dis. 2019;66(2):1037–1043. DOI:10.1111/tbed.13089
   PubMed Web of Science ®Google Scholar
• Perdomo C, Zedler U, Kühl AA, et al. Mucosal BCG vaccination induces protective lung-resident memory T cell populations against tuberculosis. mBio. 2016;7. DOI:10.1128/mBio.01686-16.
   PubMed Web of Science ®Google Scholar
• Moliva JI, Hossfeld AP, Sidiki S, et al. Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis. Mucosal Immunol. 2019;12(3):805–815. DOI:10.1038/s41385-019-0148-2
   PubMed Web of Science ®Google Scholar
• Counoupas C, Ferrell KC, Ashhurst A, et al. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. NPJ Vaccines. 2020;5(1):105. DOI:10.1038/s41541-020-00255-7
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andersen C, Rappuoli R, et al. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus calmette-guérin immunity. J Immunol. 2006;177(9):6353–6360. DOI:10.4049/jimmunol.177.9.6353
   PubMed Web of Science ®Google Scholar
• Flórido M, Muflihah H, Lin LCW, et al. Pulmonary immunization with a recombinant influenza a virus vaccine induces lung-resident CD4(+) memory T cells that are associated with protection against tuberculosis. Mucosal Immunol. 2018;11:1743–1752.
   PubMed Web of Science ®Google Scholar
• Hu Z, Wong KW, Zhao HM, et al. Sendai virus mucosal vaccination establishes lung-resident memory CD8 T cell immunity and boosts BCG-primed protection against tb in mice. Mol Ther. 2017;25(5):1222–1233. DOI:10.1016/j.ymthe.2017.02.018
   PubMed Web of Science ®Google Scholar
• Jeyanathan M, Yao Y, Afkhami S, et al. New tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol. 2018;39(5):419–433. DOI:10.1016/j.it.2018.01.006
   PubMed Web of Science ®Google Scholar
• Shim BS, Cheon IS, Lee E, et al. Development of safe and non-self-immunogenic mucosal adjuvant by recombinant fusion of cholera toxin A1 subunit with protein transduction domain. J Immunol Res. 2018;2018:9830701.
   PubMed Web of Science ®Google Scholar
• Ernst JD. Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design. Cell Host Microbe. 2018;24(1):34–42.
   PubMed Web of Science ®Google Scholar
• Stewart E, Triccas JA, Petrovsky N. Adjuvant strategies for more effective tuberculosis vaccine immunity. Microorganisms. 2019;7(8):225.
   PubMed Web of Science ®Google Scholar
• Counoupas C, Pinto R, Nagalingam G, et al. Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection. Sci Rep. 2017;7(1):8582. DOI:10.1038/s41598-017-09119-y
   PubMedGoogle Scholar
• Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01 E vaccine to prevent tuberculosis. N Engl J Med. 2019;381(25):2429–2439. DOI:10.1056/NEJMoa1909953
   PubMed Web of Science ®Google Scholar
• Todoroff J, Lemaire MM, Fillee C, et al. Mucosal and systemic immune responses to Mycobacterium tuberculosis antigen 85A following its co-delivery with CpG, MPLA or LTB to the lungs in mice. PLoS One. 2013;8(5):e63344. DOI:10.1371/journal.pone.0063344
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature. 2001;413(6857):732–738. DOI:10.1038/35099560
   PubMed Web of Science ®Google Scholar
• Pérez-Girón JV, Belicha-Villanueva A, Hassan E, et al. Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity. J Immunol. 2014;193(3):1324–1332. DOI:10.4049/jimmunol.1400222
   PubMed Web of Science ®Google Scholar
• Mookherjee N, Anderson MA, Haagsman HP, et al. Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov. 2020;19(5):311–332. DOI:10.1038/s41573-019-0058-8
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim YN, Jang YS. Cutting edge: LL-37–mediated formyl peptide receptor-2 signaling in follicular dendritic cells contributes to B cell activation in peyer’s patch germinal centers. J Immunol. 2017;198(2):629–633.
   PubMed Web of Science ®Google Scholar
• Liang Z, Liu Y, Sun X, et al. Immunoregulatory and antimicrobial activity of bovine neutrophil β-Defensin-5-Loaded PLGA nanoparticles against Mycobacterium bovis. Pharmaceutics. 2020;12(12):1172. DOI:10.3390/pharmaceutics12121172
   PubMed Web of Science ®Google Scholar
• Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28–e37. DOI:10.1016/S1473-3099(19)30625-5
   PubMed Web of Science ®Google Scholar
• Geluk A, Lin MY, van Meijgaarden KE, et al. T-cell recognition of the HspX protein of mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination. Infect Immun. 2007;75(6):2914–2921. DOI:10.1128/IAI.01990-06
   PubMed Web of Science ®Google Scholar
• Sergeeva M, Romanovskaya-Romanko E, Zabolotnyh N, et al. Mucosal influenza vector vaccine carrying TB10.4 and HspX antigens provides protection against Mycobacterium tuberculosis in Mice and Guinea Pigs. Vaccines (Basel). 2021;9(4):394. DOI:10.3390/vaccines9040394
   PubMed Web of Science ®Google Scholar
• Liang Z, Nie H, Xu Y, et al. Therapeutic effects of rosmarinic acid on airway responses in a murine model of asthma. Int Immunopharmacol. 2016;41:90–97.
   PubMed Web of Science ®Google Scholar
• Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. 2020;577(7788):95–102. DOI:10.1038/s41586-019-1817-8
   PubMed Web of Science ®Google Scholar
• Wang C, Lu J, Du W, et al. Ag85b/ESAT6-CFP10 adjuvanted with aluminum/poly-IC effectively protects guinea pigs from latent mycobacterium tuberculosis infection. Vaccine. 2019;37(32):4477–4484. DOI:10.1016/j.vaccine.2019.06.078
   PubMed Web of Science ®Google Scholar
• Kaushal D, Foreman TW, Gautam US, et al. Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against tuberculosis. Nat Commun. 2015;6(1):8533. DOI:10.1038/ncomms9533
   PubMedGoogle Scholar
• Lee-Sayer SSM, Maeshima N, Dougan MN, et al. Hyaluronan-binding by CD44 reduces the memory potential of activated murine CD8 T cells. Eur J Immunol. 2018;48(5):803–814. DOI:10.1002/eji.201747263
   PubMed Web of Science ®Google Scholar
• Lewis DJ, Huo Z, Barnett S, et al. Transient facial nerve paralysis (Bell’s palsy) following intranasal delivery of a genetically detoxified mutant of escherichia coli heat labile toxin. PLoS One. 2009;4(9):e6999. DOI:10.1371/journal.pone.0006999
   PubMed Web of Science ®Google Scholar
• Woodworth JS, Christensen D, Cassidy JP, et al. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection. Mucosal Immunol. 2019;12(3):816–826. DOI:10.1038/s41385-019-0145-5
   PubMed Web of Science ®Google Scholar
• Muruganandah V, Sathkumara HD, Pai S, et al. A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies. Sci Adv. 2020;6(10):eaaz1767. DOI:10.1126/sciadv.aaz1767
   PubMed Web of Science ®Google Scholar
• Achkar JM, Prados-Rosales R. Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis. Curr Opin Immunol. 2018;53:30–37.
   PubMed Web of Science ®Google Scholar
• Irvine EB, O’-Neil A, Darrah PA, et al. Robust IgM responses following intravenous vaccination with Bacille Calmette–Guérin associate with prevention of Mycobacterium tuberculosis infection in macaques. Nat Immunol. 2021;22(12):1515–1523. DOI:10.1038/s41590-021-01066-1
   PubMed Web of Science ®Google Scholar
• Li H, Wang XX, Wang B, et al. Latently and uninfected healthcare workers exposed to TB make protective antibodies against Mycobacterium tuberculosis. Proc Natl Acad Sci USA. 2017;114(19):5023–5028. DOI:10.1073/pnas.1611776114
   PubMed Web of Science ®Google Scholar
• Dijkman K, Sombroek CC, Vervenne RAW, et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019;25(2):255–262. DOI:10.1038/s41591-018-0319-9
   PubMed Web of Science ®Google Scholar
• Donald PR, Diacon AH, Lange C, et al. Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940. Int J Tuberc Lung Dis. 2018 Sept 1;22;(9)972–982. 10.5588/ijtld.18.0173
   PubMed Web of Science ®Google Scholar
• Darrah PA, Bolton DL, Lackner AA, et al. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge. J Immunol. 2014;193(4):1799–1811. DOI:10.4049/jimmunol.1400676
   PubMed Web of Science ®Google Scholar
• Gopal R, Rangel-Moreno J, Slight S, et al. Interleukin-17-Dependent CXCL13 mediates mucosal vaccine–induced immunity against tuberculosis. Mucosal Immunol. 2013;6(5):972–984. DOI:10.1038/mi.2012.135
   PubMed Web of Science ®Google Scholar
• Turner DL, Farber DL. Mucosal resident memory CD4 T cells in protection and immunopathology. Front Immunol. 2014;5:331.
   PubMed Web of Science ®Google Scholar
• Ogongo P, Porterfield JZ, Leslie A. Lung tissue resident memory T-cells in the immune response to Mycobacterium tuberculosis. Front Immunol. 2019;10:992.
   PubMed Web of Science ®Google Scholar
• Rakhra K, Abraham W, Wang C, et al. Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-resident memory T cells. Sci Immunol. 2021;6(57):eabd8003. DOI:10.1126/sciimmunol.abd8003
   PubMed Web of Science ®Google Scholar
• Bull NC, Stylianou E, Kaveh DA, et al. Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells. Mucosal Immunol. 2019;12(2):555–564. DOI:10.1038/s41385-018-0109-1
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, et al. MVA85A 020 trial study team. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381;(9871)1021–1028. 10.1016/S0140-6736(13)60177-4
   PubMed Web of Science ®Google Scholar
• Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020;368:eaau5480.
   PubMed Web of Science ®Google Scholar